Aliada Therapeutics

We are excited to share that Aliada Therapeutics is to be acquired by AbbVie! Together, we’ll advance our mission to drive innovation in neuroscience and bring potentially transformative?treatments to those affected by neurological disorders. A big thank you to the Aliada team for their years of dedication and impact on the field. We look forward to building a brighter future together!

#MeetTheTeam – Keith Canada, Ph.D. is VP, Head of Platform Technology, here at Aliada, with over 20 years of experience in the #biopharmaceutical industry and expertise in the discovery and preclinical development of #therapeutic modalities. https://lnkd.in/exeuz9Hd

Aliada Therapeutics is excited to support and participate in the 2024 Walk to End Alzheimer’s this Sunday, October 27th, in Cambridge. We invite you to join our team or consider making a donation to help us in the fight against Alzheimer’s. Together, we can make a difference! https://lnkd.in/gBW97Aj7

Our CSO, John Dunlop, Ph.D., discussed our MODEL? platform, an innovative blood-brain barrier-crossing technology, with Tyler Menichiello of @BioProcessOL and the potential it has to overcome challenges of therapeutic delivery for brain-related conditions. Read more here: https://lnkd.in/gMA-MZaH #Biotech #BloodBrainBarrier

?? Here's an eye-opening juxtaposition of large-molecule therapeutic engineering. ?? I just wrapped a #businessofbiotech podcast recording with Skye Bioscience Inc. leader Punit Dhillon. Among other things, we discussed the inherent advantage of the company's CB 1-targeting antibody in obesity. Namely, because it's a large molecule, it can't cross the blood-brain barrier and thus, isn't likely to incite the CNS-related side effects we've seen in so many small molecule obesity drugs. ?? On the other hand, we have this fresh Bioprocess Online column from Tyler Menichiello featuring Aliada Therapeutics CSO John Dunlop. He explains why his company is engineering an end-around approach to getting large molecules INTO the CNS, BY WAY OF the blood-brain barrier. This, he says, could change the standard (and unpleasant) intrathecal bolus injection approach to getting #biologics to the brain for CNS disorders. Sometimes nature's rules enable favorable outcomes. Other times, we have to bend those rules to create favorable outcomes.

Our CSO, John Dunlop, Ph.D., discussed our MODEL? platform with Tyler Menichiello of Bioprocess Online and the potential it has to overcome challenges of therapeutic delivery for brain-related conditions. Read more here: https://lnkd.in/gMA-MZaH #Biotech #BloodBrainBarrier

Transitioning from large to small #biopharma companies offers unique challenges and rewards. Our CSO, John Dunlop, Ph.D., sat down with Angela Gabriel of BioSpace to discuss his experiences working at biopharma companies of both sizes. Read more here: https://lnkd.in/eKc-ZCEt

#MeetTheTeam – Ryan Oliver, Ph.D., is Director of Oligo Chemistry at Aliada Therapeutics, bringing extensive experience in oligonucleotide #drugdiscovery and chemical biology in the #biotechnology sector. https://lnkd.in/exeuz9Hd

Happy 4th of July from Aliada Therapeutics! As we celebrate the independence of our nation, we’re inspired to keep pushing the boundaries of scientific innovation and improving lives. Wishing everyone a safe holiday!

#MeetTheTeam – Danijela Dukovski, Ph.D. is the Senior Director, Biology at Aliada Therapeutics. With 20 years of expertise in #cellbiology and #biochemistry, Danijela has a stellar track record, including leading drug development and advancing mitochondrial biology. https://lnkd.in/exeuz9Hd